AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29522941 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine-mirtazapine combination
Number of subjects: 662
Study 29522941 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable for overweight and obese I participants
Number of subjects: 662
Study 27622558 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled intermittent screening with malaria rapid diagnostic tests and treatment with dihydroartemisinin-piperaquine (ISTp-DP)
Number of subjects: 1873
Study 27622558 — intervention group
Group type: COMPARATOR
Intervention: Intermittent preventive therapy with sulfadoxine-pyrimethamine (IPTp-SP)
Number of subjects: 1873
Study 24755129 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor 600 mg (SAD study)
Number of subjects: 112
Study 24755129 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor 100 mg and 300 mg (MAD study)
Number of subjects: 112
Study 24755129 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor >= 100 mg (SAD study)
Number of subjects: 112
Study 24755129 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor (both studies)
Number of subjects: 112
Study 22440079 — intervention group
Group type: EXPERIMENTAL
Intervention: FRIENDS program (cognitive behavior prevention program)
Number of subjects: 638
Study 20502014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 17.4 mg/24 h patch
Number of subjects: 0
Study 20502014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 9.5 mg/24 h patch
Number of subjects: 0
Study 20502014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine capsules
Number of subjects: 0
Study 20502014 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine patches and capsules
Number of subjects: 0
Study 18377401 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 468
Study 18377401 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Intervention (MI)
Number of subjects: 468
Study 18377401 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 468
Study 16042935 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-aminolevulinic acid (ALA) and intense pulsed light (IPL)
Number of subjects: 13
Study 16042935 — intervention group
Group type: COMPARATOR
Intervention: Intense pulsed light (IPL) alone
Number of subjects: 13
Study 12443968 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% C31G co-polymer gel
Number of subjects: 0
Study 12443968 — intervention group
Group type: COMPARATOR
Intervention: 1.2% HEC gel
Number of subjects: 0
Study 12443968 — intervention group
Group type: COMPARATOR
Intervention: 2.0% N-9
Number of subjects: 0
Study 10404349 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with left ventricular systolic dysfunction (CMP)
Number of subjects: 41
Study 10404349 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with documented coronary artery disease (CAD)
Number of subjects: 41
Study 10404349 — intervention group
Group type: COMPARATOR
Intervention: Control patients with normal systolic function
Number of subjects: 41
Study 10404349 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (CMP, CAD, normal function)
Number of subjects: 41
Study 7776074 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoglobulin, 2 gm/kg (product A)
Number of subjects: 90
Study 7776074 — intervention group
Group type: COMPARATOR
Intervention: Iveegam, 2 gm/kg (product B)
Number of subjects: 90
Study 7776074 — intervention group
Group type: EXPERIMENTAL
Intervention: Both products A and B
Number of subjects: 90
Study 2176518 — intervention group
Group type: EXPERIMENTAL
Intervention: rHu‐EPO (erythropoietin)
Number of subjects: 22
Study 2176518 — intervention group
Group type: COMPARATOR
Intervention: Control group (no erythropoietin)
Number of subjects: 22
Study 375850 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen at 10 mg per kg body weight
Number of subjects: 0
Study 375850 — intervention group
Group type: COMPARATOR
Intervention: Aspirin at 80 mg per kg body weight
Number of subjects: 0
Study 31755280 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual educational leaflet
Number of subjects: 136
Study 31755280 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no leaflet)
Number of subjects: 136
Study 28107821 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 20 mg administered when the dominant follicle reached 12 mm
Number of subjects: 45
Study 28107821 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 20 mg administered when the dominant follicle reached 18 mm
Number of subjects: 45
Study 28107821 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 20 mg administered on the first day following ovulation (post‐ovulation)
Number of subjects: 45
Study 28107821 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment withheld)
Number of subjects: 45
Study 27186989 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizers
Number of subjects: 0
Study 27186989 — intervention group
Group type: COMPARATOR
Intervention: Metered dose inhalers (MDIs) with spacers
Number of subjects: 0
Study 24548781 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Information Leaflets (PILs)
Number of subjects: 20
Study 24548781 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation tool for PILs
Number of subjects: 20
Study 24548781 — intervention group
Group type: EXPERIMENTAL
Intervention: PILs
Number of subjects: 20
Study 22426749 — intervention group
Group type: EXPERIMENTAL
Intervention: HSCT (Hematopoietic Stem Cell Transplantation)
Number of subjects: 107
Study 22426749 — intervention group
Group type: COMPARATOR
Intervention: Transplanted patients
Number of subjects: 107
Study 19752154 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise (20 min cycle-ergometry at approximately 60% of age-predicted maximum heart rate)
Number of subjects: 52
Study 19752154 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (control group)
Number of subjects: 52
Study 17574796 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD
Number of subjects: 167
Study 17574796 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD
Number of subjects: 167
Study 17574796 — intervention group
Group type: COMPARATOR
Intervention: CD alone
Number of subjects: 167
Study 15979021 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75 mg
Number of subjects: 60
Study 15979021 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 150 mg
Number of subjects: 60
Study 15979021 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine groups
Number of subjects: 60
Study 15979021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12180734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetylated fatty acids (CFA)
Number of subjects: 64
Study 12180734 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vegetable oil)
Number of subjects: 64
Study 10599994 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet with preprandial exercise (Ex-FAT)
Number of subjects: 7
Study 10599994 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet with postprandial exercise (FAT-Ex)
Number of subjects: 7
Study 10599994 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet with preprandial exercise (Ex-CHO)
Number of subjects: 7
Study 10599994 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet with postprandial exercise (CHO-Ex)
Number of subjects: 7
Study 8961722 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg dextroamphetamine (10 mg doses at midnight, 4 a.m., and 8 a.m.)
Number of subjects: 0
Study 1301641 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine administered via femoral block
Number of subjects: 0
Study 1301641 — intervention group
Group type: COMPARATOR
Intervention: Meperidine administered intravenously
Number of subjects: 0
Study 1301641 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine administered via interscalene block
Number of subjects: 0
Study 3886301 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg) with chlorthalidone (12.5 mg)
Number of subjects: 100
Study 3886301 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg) alone
Number of subjects: 100
Study 3886301 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (12.5 mg) alone
Number of subjects: 100
Study 31047802 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-induction PET response after first-line immunochemotherapy
Number of subjects: 0
Study 31047802 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete metabolic response
Number of subjects: 0
Study 31047802 — intervention group
Group type: EXPERIMENTAL
Intervention: No complete metabolic response
Number of subjects: 0
Study 29277698 — intervention group
Group type: EXPERIMENTAL
Intervention: High fertility voice stimuli
Number of subjects: 33
Study 29277698 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice ratings task
Number of subjects: 33
Study 29277698 — intervention group
Group type: COMPARATOR
Intervention: Low fertility voice stimuli
Number of subjects: 33
Study 26382733 — intervention group
Group type: EXPERIMENTAL
Intervention: Epratuzumab 100 mg Q2W
Number of subjects: 20
Study 26382733 — intervention group
Group type: EXPERIMENTAL
Intervention: Epratuzumab 400 mg Q2W
Number of subjects: 20
Study 26382733 — intervention group
Group type: EXPERIMENTAL
Intervention: Epratuzumab 600 mg QW
Number of subjects: 20
Study 26382733 — intervention group
Group type: EXPERIMENTAL
Intervention: Epratuzumab 1200 mg Q2W
Number of subjects: 20
Study 26382733 — intervention group
Group type: EXPERIMENTAL
Intervention: Epratuzumab (all doses)
Number of subjects: 20
Study 26382733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24689982 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing a pro-anorexia website
Number of subjects: 124
Study 24689982 — intervention group
Group type: COMPARATOR
Intervention: Viewing control websites (fashion, home decoration, automutilation)
Number of subjects: 124
Study 24438999 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based group cognitive-behavioral intervention
Number of subjects: 0
Study 24438999 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 0
Study 22553407 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 22553407 — intervention group
Group type: COMPARATOR
Intervention: Midazolam plus Fentanyl (M/F)
Number of subjects: 0
Study 19403595 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP of 10 cm H2O (Group P)
Number of subjects: 60
Study 19403595 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory pressure of 40 cm H2O for 15 s once (Group R)
Number of subjects: 60
Study 19403595 — intervention group
Group type: EXPERIMENTAL
Intervention: Group R recruitment followed by PEEP 10 cm H2O (Group RP)
Number of subjects: 60
Study 19403595 — intervention group
Group type: EXPERIMENTAL
Intervention: Group RP recruitment but with the inspiratory manoeuvre repeated every 10 min (Group RRP)
Number of subjects: 60
Study 17330625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 174
Study 17330625 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 174
Study 15681764 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin (1 mg/day)
Number of subjects: 187
Study 15681764 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin (10 mg/day)
Number of subjects: 187
Study 11120935 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg orally, 3 times per week for 6 months
Number of subjects: 49
Study 11120935 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 3 times per week for 6 months
Number of subjects: 49
Study 11120935 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 49
Study 9613081 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of long-acting propranolol hydrochloride-betacap (Natko, India)
Number of subjects: 48
Study 7626966 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors (treatment duration: 10 to 12 weeks)
Number of subjects: 21
Study 1720479 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 or 5 mg b.i.d.)
Number of subjects: 0
Study 1720479 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (12.5 or 25 mg b.i.d.)
Number of subjects: 0
Study 6184938 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with dextran
Number of subjects: 60
Study 6184938 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose heparin
Number of subjects: 60
Study 6184938 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 31138247 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin infusion (10 ml/kg) administered slowly (180 min)
Number of subjects: 64
Study 31138247 — intervention group
Group type: COMPARATOR
Intervention: 5% albumin infusion (10 ml/kg) administered rapidly (30 min)
Number of subjects: 64
Study 28376836 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group
Number of subjects: 100
Study 28376836 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no acupuncture) group
Number of subjects: 100
Study 25837245 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (NH)
Number of subjects: 0
Study 25837245 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (HH)
Number of subjects: 0
Study 25837245 — intervention group
Group type: EXPERIMENTAL
Intervention: Long duration exercise (60 minutes)
Number of subjects: 0
Study 25837245 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration exercise (10 minutes)
Number of subjects: 0
Study 25837245 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute mountain sickness (AMS)
Number of subjects: 0
Study 25837245 — intervention group
Group type: COMPARATOR
Intervention: Normobaric normoxia (NN)
Number of subjects: 0
Study 24184066 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Intervention (MBI) for 8 weeks
Number of subjects: 27
Study 24184066 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 27
Study 22746358 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-guided pelvic floor muscle training (PFMT) once weekly for 12 months (Group A, n=42)
Number of subjects: 85
Study 22746358 — intervention group
Group type: COMPARATOR
Intervention: Standard care/training (Group B, n=43)
Number of subjects: 85
Study 19638646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytological surveillance every six months in primary care (n=2223)
Number of subjects: 4439
Study 19638646 — intervention group
Group type: COMPARATOR
Intervention: Referral for colposcopy (n=2216)
Number of subjects: 4439
Study 19638646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytological surveillance
Number of subjects: 4439
Study 19638646 — intervention group
Group type: COMPARATOR
Intervention: Immediate colposcopy
Number of subjects: 4439
Study 17334706 — intervention group
Group type: EXPERIMENTAL
Intervention: Large neutral amino acids (LNAA)
Number of subjects: 0
Study 17334706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15142218 — intervention group
Group type: EXPERIMENTAL
Intervention: Once a day toothcleaning
Number of subjects: 20
Study 15142218 — intervention group
Group type: COMPARATOR
Intervention: Once in 2 days toothcleaning
Number of subjects: 20
Study 11422148 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral montelukast (10 mg tablet for adults, 5 mg chewable tablet for children)
Number of subjects: 436
Study 11422148 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (beclomethasone 200 microg twice daily for adults, 100 microg or equivalent three times daily for children)
Number of subjects: 436
Study 9727891 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg troglitazone
Number of subjects: 222
Study 9727891 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg troglitazone
Number of subjects: 222
Study 9727891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 9727891 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone in open-label extension
Number of subjects: 222
Study 8051884 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus size 3
Number of subjects: 49
Study 8051884 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus size 5
Number of subjects: 49
Study 1821247 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (reduction of serum antimuscarinic activity)
Number of subjects: 34
Study 1821247 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 34
Study 6941465 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 170
Study 6941465 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 170
Study 31469243 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8mg/kg intravenous infusions
Number of subjects: 0
Study 31469243 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 50mg subcutaneous injections
Number of subjects: 0
Study 30777017 — intervention group
Group type: EXPERIMENTAL
Intervention: Framed intervention (prevention perspective)
Number of subjects: 111
Study 30777017 — intervention group
Group type: EXPERIMENTAL
Intervention: Framed intervention (promotion perspective)
Number of subjects: 111
Study 30777017 — intervention group
Group type: COMPARATOR
Intervention: Neutral framing (control)
Number of subjects: 111
Study 28634121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation solution (300 mg, twice daily)
Number of subjects: 0
Study 25028283 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing‐2‐gether (n = 89)
Number of subjects: 175
Study 25028283 — intervention group
Group type: COMPARATOR
Intervention: Education-as-usual control condition (n = 86)
Number of subjects: 175
Study 24301236 — intervention group
Group type: EXPERIMENTAL
Intervention: Abobotulinum toxin A (ABO) at doses ranging from 120 to 250 U
Number of subjects: 90
Study 24301236 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of ABO in the perioral area
Number of subjects: 90
Study 21332412 — intervention group
Group type: EXPERIMENTAL
Intervention: Barnidipine
Number of subjects: 0
Study 21332412 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 19584187 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy (0.012 mg/kg every second day, approximately 2.5 IU)
Number of subjects: 158
Study 19584187 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 158
Study 17582635 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-releasing drug-eluting stents (sirolimus and paclitaxel)
Number of subjects: 0
Study 17582635 — intervention group
Group type: COMPARATOR
Intervention: Rapid-releasing drug-eluting stents (sirolimus and paclitaxel)
Number of subjects: 0
Study 15198763 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (0.8 mg)
Number of subjects: 2219
Study 15198763 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (0.4 mg)
Number of subjects: 2219
Study 15198763 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (0.8 mg)
Number of subjects: 2219
Study 15198763 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 2219
Study 15198763 — intervention group
Group type: EXPERIMENTAL
Intervention: Both misoprostol groups
Number of subjects: 2219
Study 15198763 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall perception of medical abortion
Number of subjects: 2219
Study 15198763 — intervention group
Group type: EXPERIMENTAL
Intervention: Future abortion preferences
Number of subjects: 2219
Study 11394732 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 893
Study 11394732 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bupropion SR and nicotine patch
Number of subjects: 893
Study 11394732 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch
Number of subjects: 893
Study 11394732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 893
Study 9555354 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive management group (educational sessions)
Number of subjects: 53
Study 8072263 — intervention group
Group type: EXPERIMENTAL
Intervention: AN69 membranes during anaphylactoid reactions
Number of subjects: 22
Study 8072263 — intervention group
Group type: EXPERIMENTAL
Intervention: AN69 membranes during symptom-free sessions
Number of subjects: 22
Study 8072263 — intervention group
Group type: COMPARATOR
Intervention: CuprophanR membranes
Number of subjects: 22
Study 8072263 — intervention group
Group type: COMPARATOR
Intervention: HemophanR membranes
Number of subjects: 22
Study 8072263 — intervention group
Group type: COMPARATOR
Intervention: PolysulfoneR membranes
Number of subjects: 22
Study 8072263 — intervention group
Group type: EXPERIMENTAL
Intervention: AN69 membranes (specific patient with hypersensitivity)
Number of subjects: 22
Study 2895214 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily
Number of subjects: 116
Study 2895214 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 116
Study 2895214 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 116
Study 31509849 — intervention group
Group type: EXPERIMENTAL
Intervention: RCS‐01 (25 × 10^6 cultured, autologous cells derived from anagen hair follicle non‐bulbar dermal sheath)
Number of subjects: 0
Study 31509849 — intervention group
Group type: EXPERIMENTAL
Intervention: RCS‐01
Number of subjects: 0
Study 31509849 — intervention group
Group type: COMPARATOR
Intervention: Cryomedium (placebo)
Number of subjects: 0
Study 31509849 — intervention group
Group type: COMPARATOR
Intervention: Needle penetration without injection (placebo)
Number of subjects: 0
Study 30912296 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (GT) treatment for 4 months
Number of subjects: 200
Study 30912296 — intervention group
Group type: COMPARATOR
Intervention: Hot water (HW) ingestion for 4 months (after GT treatment in Grp1)
Number of subjects: 200
Study 30912296 — intervention group
Group type: COMPARATOR
Intervention: Hot water (HW) ingestion for 4 months (before GT treatment in Grp2)
Number of subjects: 200
Study 30912296 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (GT) treatment for 4 months (after HW ingestion in Grp2)
Number of subjects: 200